Company: ZCARW
Filing Date: 2025-05-05
Form Type: S-1
Source: 0001213900-25-039778
Chunk: 3

Company: Zoomcar Holdings, Inc.
Filing Date: 2025-05-05
Form: S-1
Chunk 3
---
 that our Common Stock and Public Warrants will be delisted from trading on Nasdaq”. We are an “emerging growth company,” as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See “ Prospectus Summary - Emerging Growth Company.” Investing in our securities involves risks, including the risk that our Common Stock is delisted from trading on the Nasdaq Market imminently. See “ Risk Factors” beginning on page 14 of this prospectus, and in particular, the risk factor titled “Even if we close this offering it is almost certain that our Common Stock and Public Warrants will be delisted from trading on Nasdaq”, and elsewhere in this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

|                                           |     | Per Share |     | Per        
 Pre-Funded 
 Warrant    |     | Total |
|:------------------------------------------|:----|:----------|:----|:-----------|:----|:------|
| Public offering price                     |     | $         |     | $          |     | $     |
| Underwriting discounts and commissions(1) |     | $         |     | $          |     | $     |
| Proceeds to us (before expenses)          |     | $         |     | $          |     | $     |

| (1) | The underwriter will receive an underwriting discount equal to 8.0% of the gross proceeds from the sale of securities in the offering. We have also agreed to reimburse the underwriter for certain expenses in connection with this offering. See “Underwriting” for additional information regarding total underwriting compensation, including information on underwriting discounts and offering expenses. |

We have granted the underwriter an option exercisable within 45 days of the date of this prospectus to purchase from us up to 552,825 additional shares of Common Stock at a price of $4.07 per share, less the underwriting discounts and commissions to cover over-allotments, if any. If this over-allotment option for shares of Common Stock is exercised in full, the total offering price to the public will be approximately $17,250,000, and the total net proceeds, before expenses and after deducting the underwriting discounts described above, to us will be approximately $15,870,000(based upon an assumed public offering price of $4.07 per share